Next Article in Journal
MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells
Next Article in Special Issue
Can We Predict the Efficacy of Anti-TNF-α Agents?
Previous Article in Journal
Principal Aspects Regarding the Maintenance of Mammalian Mitochondrial Genome Integrity
Previous Article in Special Issue
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
Open AccessArticle

Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study

Department of Dental Medicine, Division of Periodontology, Karolinska Institutet, Alfred Nobels Allé 8, SE-141 52 Huddinge, Sweden
Department of Medicine, Solna, Karolinska Institutet, SE-171 76 Stockholm, Sweden
GastroCentrum, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2017, 18(8), 1827;
Received: 31 July 2017 / Revised: 15 August 2017 / Accepted: 17 August 2017 / Published: 22 August 2017
Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α4β7 integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot study, we included 11 IBD patients (8 Crohn’s disease, 3 ulcerative colitis) previously non-respondent to anti-tumor necrosis factor (TNF)-agents. Patients received vedolizumab at week 0, 2 and 6 and were evaluated for clinical efficacy at week 10. Clinical characteristics and routine laboratory parameters were obtained and patients were classified as responders or non-responders. Expression of 21 chemokines in serum was measured using Proximity Extension Assay and related to clinical outcome. At week 10, 6 out of 11 patients had clinically responded. Overall expression of CCL13 increased after treatment. In non-responders, expression of CCL13 and CXCL8 increased after treatment, and CCL20 and CXCL1 expressions were higher compared to responders. In responders, CCL28 decreased after treatment. C-reactive protein (CRP) correlated negatively with 6 chemokines before therapy, but not after therapy. Systemic CCL13 expression increases in IBD-patients after vedolizumab therapy and several chemokine levels differ between responders and non-responders. An increased CCL13-level when starting vedolizumab treatment, might indicate potential prognostic value of measuring chemokine levels when starting therapy with vedolizumab. This study provides new information on modulation of systemic chemokine levels after vedolizumab treatment. View Full-Text
Keywords: vedolizumab; chemokines; inflammatory bowel disease; biologics vedolizumab; chemokines; inflammatory bowel disease; biologics
Show Figures

Figure 1

MDPI and ACS Style

Zwicker, S.; Lira-Junior, R.; Höög, C.; Almer, S.; Boström, E.A. Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study. Int. J. Mol. Sci. 2017, 18, 1827.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

Back to TopTop